Logo

BioTheranostics Inks Contract with PPO Prime Health Services

Apr 09, 2014 | staff reporter

NEW YORK (GenomeWeb News) – Genomic cancer test provider BioTheranostics today announced a contract with preferred provider network Prime Health Services for coverage of BioTheranostics' tests for breast cancer and metastatic disease.

Members of Prime Health now have access to San Diego-based BioTheranostics' molecular-based tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, and CancerType ID for diagnosing metastatic cancer.

Based in Brentwood, Tenn., Prime Health has more than 700,000 providers and facilities across the US.

BioTheranostics last week announced a contract with PPO Three Rivers Provider Network.

Filed under

Diagnostics
Cancer
Molecular Diagnostics
BioTheranostics
Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.